This year's PharmSci 360 will close with a plenary on fixing drug development economics given by Averin's Dr Berry.
|Articles|June 15, 2015
- BioPharm International-06-15-2015
- Volume 2015 eBook
- Issue 1
Protecting Intellectual Property in Engagements with CMOs
Author(s)Jennifer L. Collins
Important IP contractual provisions should be included when working with CMOs.
Advertisement
Biotechnology and pharmaceutical companies often engage contract CMOs to assist with the development of their drugs. This type of arrangement naturally involves the development of intellectual property (IP), so it is important for both the CMO and the sponsor to identify pre-existing intellectual property and also define how rights to new IP will be allocated, protected, and enforced by and between the companies.
Articles in this issue
over 11 years ago
QRM Tools for Contract Biomanufacturingover 11 years ago
Fill/Finish Trendsover 11 years ago
Biopharma Advances Demand Specialized Expertiseover 11 years ago
Taking a “Development-by-Design” Approach to Cell TherapiesAdvertisement
Related to this article
Dr Karunakar Sukuru of Catalent explains how lipid-based softgels address physiological barriers to oral peptide delivery as approvals increase.
A patient with relapsing MS died of septic pneumonia 44 days after zola-cel CAR T infusion, as all 60 dose level 2 patients stayed off DMTs.
FNIH CEO Dr Julie Gerberding will open the October 25-28 meeting with a talk on using AI, adaptive trials, and alternative methods in drug development.
Phase 1 HCXT-2001, an oral macrocyclic IL-23R peptide, could be paired with emvistegrast as a daily oral IBD treatment, according to Gilead.
Roche gains exclusive global rights to ZW209, a DLL3×CD3×CD28 trispecific T-cell engager designed for CD28 co-stimulation. A phase 1 study in small cell lung cancer and other neuroendocrine tumors is underway.
A Treasury proposed rule would restrict certain US investments in biotechnology in China and other countries of concern, raising questions about how cross-border licensing and joint venture deals will be treated.
Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
Advertisement
Advertisement
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
3
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
4
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
5